1-deoxynojirimycin has been researched along with Nerve Degeneration in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hawlitschka, A; Hovakimyan, M; Lukas, J; Maass, F; Petersen, J; Rolfs, A; Schmitt, O; Witt, M; Wree, A | 1 |
| Addobbati, R; Barone, R; Bembi, B; Butters, T; Cariati, R; Ciana, G; Fernandez-Guillen, L; Grasso, D; Guerci, VI; Marchetti, F; Pittis, MG | 1 |
| Baek, RC; Kasperzyk, JL; Platt, FM; Seyfried, TN | 1 |
3 other study(ies) available for 1-deoxynojirimycin and Nerve Degeneration
| Article | Year |
|---|---|
Reduced cerebellar neurodegeneration after combined therapy with cyclodextrin/allopregnanolone and miglustat in NPC1: a mouse model of Niemann-Pick type C1 disease.
Topics: 1-Deoxynojirimycin; Animals; Cell Count; Cerebellum; Cyclodextrins; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Mice; Nerve Degeneration; Neurons; Niemann-Pick Disease, Type C; Pregnanolone | 2015 |
Substrate reduction therapy in the infantile form of Tay-Sachs disease.
Topics: 1-Deoxynojirimycin; Craniofacial Abnormalities; Electroencephalography; Evoked Potentials, Auditory, Brain Stem; Evoked Potentials, Visual; Female; Humans; Infant; Nerve Degeneration; Tay-Sachs Disease | 2006 |
N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Topics: 1-Deoxynojirimycin; Animals; Animals, Newborn; beta-Hexosaminidase alpha Chain; Brain; Brain Chemistry; Disease Models, Animal; Down-Regulation; G(M2) Ganglioside; Gangliosides; Glycosphingolipids; Mice; Mice, Knockout; Nerve Degeneration; Neuraminidase; Sandhoff Disease; Treatment Outcome | 2008 |